
-
BioXcel Therapeutics Inc NasdaqCM:BTAI BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Location: 555 Long Wharf Drive, New Haven, CT, 06511, United States | Website: https://www.bioxceltherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
82.31M
Cash
31.01M
Avg Qtr Burn
-16.59M
Short % of Float
2.41%
Insider Ownership
8.61%
Institutional Own.
11.02%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IGALMI (dexmedetomidine) (BXCL501) Details Mental health, Bipolar depression, Schizophrenia, Bipolar disease | Approved Quarterly sales | |
BXCL501 Details Bipolar depression, Bipolar disease, Mental health, Schizophrenia, Agitation | Phase 3 Data readout | |
BXCL501 Details Dementia, Alzheimer's disease, Agitation in Alzheimer's Disease | Phase 3 Initiation | |
BXCL701 + KEYTRUDA Details Neuroendocrine prostate cancer, Castration-resistant prostate cancer | Phase 2b Update | |
BXCL701 + KEYTRUDA Details Solid tumor/s, Cancer, Pancreatic cancer | Phase 2 Data readout | |
BXCL501 + Duloxetine Details Major depressive disorder | Phase 2 Initiation | |
BXCL501 Details Mental health, Acute stress disorder | Phase 2a Initiation | |
BXCL501 Details Opioid use disorder | Phase 1 Update | |
BXCL501 Details Mental health, Delirium, Agitation | Failed Discontinued |